News
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...
The company is paying $350 million upfront, and potentially $1.2 billion overall, for a radiopharmaceutical for prostate ...
Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results